Biogen (BIIB) Asset Utilization Ratio (2009 - 2026)
Biogen (BIIB) posted Asset Utilization Ratio of 0.33 for Q2 2026, down 3.43% on a QoQ basis from 0.34 in Q1 2026, and down 8.17% year-over-year from 0.35 in Q2 2025.
Analysis
Biogen (BIIB) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Biogen has reported Asset Utilization Ratio for 18 years, with the latest figure at 0.33 in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio fell 8.17% year-over-year to 0.33 in Q2 2026; TTM through Jun 2026 was 0.33, a 8.17% decrease from a year earlier, with the FY2025 full-year figure at 0.34, down 2.39% from the prior year.
- Asset Utilization Ratio was 0.33 for Q2 2026 at Biogen, down from 0.34 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.46 in Q1 2022, with the low at 0.33 in Q2 2026.
- Average Asset Utilization Ratio over 5 years is 0.37, with a median of 0.36 recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Asset Utilization Ratio dropped 13.21% in 2023, then grew 0.36% in 2025.
- Over 5 years, Asset Utilization Ratio stood at 0.41 in 2022, then retreated by 13.21% to 0.36 in 2023, then fell by 3.94% to 0.34 in 2024, then decreased by 1.76% to 0.34 in 2025, then slipped by 3.42% to 0.33 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.33 (Q2 2026), 0.34 (Q1 2026), and 0.34 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 0.54 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.33 |
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.34 |
| Sep 30, 2025 | 0.35 |
| Jun 30, 2025 | 0.35 |
| Mar 31, 2025 | 0.35 |
| Dec 31, 2024 | 0.34 |
| Sep 30, 2024 | 0.35 |
| Jun 30, 2024 | 0.36 |
| Mar 31, 2024 | 0.36 |
| Dec 31, 2023 | 0.36 |
| Sep 30, 2023 | 0.37 |
| Jun 30, 2023 | 0.40 |
| Mar 31, 2023 | 0.41 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.42 |
| Jun 30, 2022 | 0.44 |
| Mar 31, 2022 | 0.46 |
| Dec 31, 2021 | 0.46 |
| Sep 30, 2021 | 0.46 |